AVI BioPharma Will Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
PORTLAND, Ore. — April 28, 2005 — AVI BioPharma, Inc. (Nasdaq: AVII), today announced that President Alan Timmins will present an update on the company’s strategy at The Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on Thursday, May 5, 2005, at 11:15 a.m. Paris time. The presentation will take place at the Intercontinental Hotel in Paris, France.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NeuGene® antisense drugs. AVI’s lead NeuGene antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI’s antiviral program uses NeuGene antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus and Ebola virus. More information about AVI is available on the company’s Web site at http://www.avibio.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.